{"id":"W2947663188","doi":"10.1200/jco.2019.37.15_suppl.4569","title":"KEYNOTE-427 cohort B: First-line pembrolizumab (pembro) monotherapy for advanced non‒clear cell renal cell carcinoma (NCC-RCC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Cohort; Chromophobe cell; Pembrolizumab; Renal cell carcinoma; Internal medicine; Population; Clinical endpoint; Histology; Urology; Oncology; Clear cell; Surgery; Cancer; Clinical trial; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001043985,0.0007535575,0.0008139604,0.0003606767,0.00063903,0.0008247725,0.0007720047,0.000888614,0.0116184],"category_scores_gemma":[0.00081156,0.0002991363,0.00087601,0.0003389689,0.0003445835,0.0005746068,0.0004937212,0.001476819,0.002197146],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001067338,"about_ca_system_score_gemma":0.002096244,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002453981,"about_ca_topic_score_gemma":0.005289587,"domain_scores_codex":[0.9996431,0.0001108131,0.00002740688,0.00009175426,0.00005686849,0.00007009942],"domain_scores_gemma":[0.9992647,0.00007038667,0.000130162,0.00008178221,0.0000889899,0.0003639442],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.6743187,0.03812549,0.04093788,0.002482799,0.003013399,0.0009736203,0.000304866,0.002340457,0.0321409,0.0009098328,0.07993159,0.1245204],"study_design_scores_gemma":[0.5891169,0.2240423,0.09781788,0.0003242204,0.001755305,0.001923379,0.0002075129,0.001635683,0.009599661,0.000701739,0.07280597,0.00006954087],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.931179,0.00414428,0.001254054,0.000762807,0.0002842207,0.01171984,0.03676234,0.0001675925,0.01372593],"genre_scores_gemma":[0.9086768,0.002247543,0.003058549,0.002684068,0.000355591,0.009270858,0.0616319,0.00006419003,0.01201052],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0116184,"threshold_uncertainty_score":0.03886741,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05779333220240377,"score_gpt":0.3926858374260705,"score_spread":0.3348925052236668,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}